

**A RETROSPECTIVE STUDY OF THYROID HORMONE AND GROWTH IN  
PEDIATRICS: RELATIONSHIPS WITH GROWTH HORMONE EFFECTS  
CORRELATION WITH OBESITY IN RIYADH, SAUDI ARABIA**

**Dr. Abdullah Hamad Alfaris\*, Dr. Faisal Mujeb Alshareef, Dr. Feras Ghazi Alhazmi, Dr. Ahmed Enad Alenazi, Abdullah Samir Aldarwish, Ziyad Alluwaymi, Saif Saad Altuwairqi, Abdulaziz Alqarni, Abdullah Alkahtani, Abdulwahab Alshamrani, Fahad Bin Abbas, Faisal Alsukairan, Mohammed Alfadhel, Mohammad Kaled Almazied and Khalid Ahmed Aljasser**

Saudi Arabia.

\*Corresponding Author: Dr. Abdullah Hamad Alfaris

Saudi Arabia.

Article Received on 10/07/2021

Article Revised on 31/07/2021

Article Accepted on 20/08/2021

**INTRODUCTION**

Research in the field of growth endocrinology has been mainly focused on growth hormone (GH) and growth deficiency correlation of risk of obesity. Morbidly obese subjects are characterized by multiple endocrine abnormalities, and these are paralleled by unfavorable changes in body composition. In obese individuals, either 24-h spontaneous or stimulated GH secretion is impaired without an organic pituitary disease and the severity of the secretory defect is proportional to the degree of obesity. The aim of the present study was to investigate the relationships between decreased GH secretion and body composition in a group of pediatric populations. However, it appears that GH does not always control growth rate. For instance, it does not clearly influence intra-uterine growth in addition, GH does not always clearly stimulate somatomedin production, particularly during food restriction and fetal life, associated with a reduced T3 production, suggesting a significant influence of thyroid function on GH action, and more generally, on body growth.

**OBJECTIVE AND METHOD****Objective**

A retrospective study of thyroid hormone and growth in Pediatrics.

Correlation effect of obesity in Security Forces Hospital, Riyadh. We assessed whether a resolved single event of growth hormone deficient in childhood was associated with obesity.

In order to measure the height and Weight of pediatric population who have growth delayed, before and after administer growth and thyroid hormone

This research has been conducted at public military hospital at Saudi Arabi in Riyadh city in 2021.

**Methodology**

A retrospective study was done in which a convenience sample was assembled from security force hospital at Riyadh. A total of 273 of growth hormone deficient (GHD) children with age range of 1 to 15 years old were investigated for their body weight and body height in the beginning of the study. On average, the children were enrolled in the study at 9 years old ( $SD = 2.64$ ) and completed at 13 years old ( $SD = 2.52$ ). This shows that on average, each child's height and weight were measured at 3.27 years of age ( $SD = 2.11$ ). In the beginning of the study, the mean of body height was 124.51 cm ( $SD = 15.28$ ) and recorded to reach 144.92

( $SD = 14.52$ ) at the end of the study. Similarly, the mean of body weight was 26.51 ( $SD = 10.76$ ) at the end of study and show an increase to 41.80 ( $SD = 15.18$ ) at the end of the study. These findings are summarized in Table 1. The distributions of height and weight at the beginning and the end of the study are also displayed in Figure 1.

**DISCUSSION**

A retrospective study at turned into completed in which a convenience sample was assembled from security force hospital at Riyadh. a complete of 273 of growth hormone deficient (GHD) youngsters with age range of 1 to 15 years vintage were investigated for their frame of weight and height within the starting of the observe.

On common, the patients have been enrolled within the look at at 9 years old ( $SD = 2.64$ ) and finished at 13 years old ( $SD = 2.52$ ). This shows that on common, each child height and weight have been measured at 3.27 years of age ( $SD = 2.11$ ). at the beginning of the observe, the imply of body height turned into 124.51 cm ( $SD = 15.28$ ) and recorded to reach 144.92 ( $SD = 14.52$ ) at the cease of the study. There's a strong relation between obesity and TSH.<sup>[1]</sup>

Most of the obese children showed a subnormal plasma GH reaction to GHRH and the imply plasma GH

incorporated location (IC-GH) following stimulation changed into substantially smaller in overweight than on top of things children.<sup>[2]</sup>

Current evidence shows that leptin, that made of adipocyte-particular ob gene, exerts a stimulating impact on GH launch in rodents; need to the identical preserve proper in man, the coexistence of high leptin and low GH serum ranges in human obesity might fit in well with the concept of leptin resistance in this circumstance.<sup>[3]</sup>

In other studies, GHD were identified in obesity at 27.3% no matter the gender, also GH peak showed negative correlation with BMI and age, and positive correlation with IGF-I.<sup>[4]</sup>

We found out, out of 273 patients, 258 (94.5%) received levothyroxine treatment and the relaxation 15 (5.5%) did not get hold of the remedy (control group). The growth rate is described as the annual rate of an increase in youngsters' weight and height.


The Levene's test has shown us that the independent t-test for comparing weight growth rate between males and females should be carried under the assumption of equal variances since the p-value is greater than 0.05 ( $F = 0.756, p = 0.278$ ).

## RESULT

A total of 273 of growth hormone deficient (GHD) children with age range of 1 to 15 years old were investigated for their body weight and body height in the beginning of the study. On average, the children were enrolled in the study at 9 years old ( $SD = 2.64$ ) and completed at 13 years old ( $SD = 2.52$ ). This shows that on average, each child's height and weight were measured at 3.27 years of age ( $SD = 2.11$ ). In the beginning of the study, the mean of body height was 124.51 cm ( $SD = 15.28$ ) and recorded to reach 144.92 ( $SD = 14.52$ ) at the end of the study. Similarly, the mean of body weight was 26.51 ( $SD = 10.76$ ) at the end of study and show an increase to 41.80 ( $SD = 15.18$ ) at the end of the study. These findings are summarize in Table 1. The distributions of height and weight at the beginning and the end of the study are also displayed in Figure 1.

**Table 1: Summary statistics.**

Variable	N	Mean	Std. Deviation	Minimum	Maximum
Age (years)					
Study start	273	9.76	2.64	1	15
Study end	273	13.00	2.52	3	18
Study Duration	273	3.27	2.11	1	12
Height (cm)					
Study start	273	124.51	15.28	72.0	164.0
Study end	273	144.92	14.52	92.5	169.7
Height increase	273	20.41	13.57	0.0	73.6
Height growth rate	273	6.31	2.51	0.0	17.1
Weight (kg)					
Study start	273	26.51	10.76	8.26	80.8
Study end	273	41.80	15.18	12	95.7
Weight increase	273	15.29	12.02	-6.15	77.0
Weight growth rate	273	4.89	3.36	-1.54	28.75



**Figure 1: Boxplots for children's weight (left panel) and height (right panel) at the beginning and the end of the study.**

Out of 273 patients, 258 (94.5%) received levothyroxine treatment and the rest 15 (5.5%) did not receive the treatment (control group). In this study, we would like to investigate whether there is any significant different between the treatment and control groups in children's weight and height growth rate. The growth rate is defined as the annual rate to an increase of children's weight and height. This research hypothesis can be formulated into the following null and alternative hypotheses:

**H<sub>0</sub>**: there is no significant different in the growth rate of weight (height) between treatment and control groups


**H<sub>1</sub>**: there is a significant different in the growth rate of weight (height) between treatment and control groups

An independent sample t-test is carried out to answer this hypothesis assuming that the two population of treatment and control groups have equal variances. This is confirmed from the Levene's test for testing equality of variance. The results indicate that the weight growth rate for treatment and control groups have equal variances since the p-value is not less than 0.05 ( $F = 1.436$ ,  $p = 0.232$ ). Similarly, the height growth rate for both groups

also satisfy the assumption of equal variances since the p-value is not less than 0.05 ( $F = 0.024$ ,  $p = 0.877$ ).

Figure 2 shows that the growth rate for weight was higher among patients who received the treatment ( $M = 4.917$ ,  $SD = 3.430$ ) than those who did not receive the treatment ( $M = 4.440$ ,  $SD = 1.928$ ). However, the t-test indicates that the mean difference between the two groups was not statistically significant since the p-value is greater than 0.05 ( $t(271) = 0.533$ ,  $p = 0.594$ ). This shows that there is no significant difference in weight gain between patients who were treated with growth hormone and those who were not (Table 2).

The growth rate for height was also higher among patients who received the treatment ( $M = 6.415$ ,  $SD = 2.484$ ) than those who did not receive the treatment ( $M = 4.547$ ,  $SD = 2.448$ ) as displayed in Figure 2. The t-test also confirms that the difference between the two groups was statistically significant since the p-value is less than 0.05 ( $t(271) = 2.833$ ,  $p = 0.005$ ). This shows that we have enough evident to conclude that the growth hormone treatment can increase height gain at higher rates than the control group (Table 2).




**Figure 2:** Plots of 95% confidence interval for growth rate of weight and height for treatment and control groups.

**Table 2:** Results for independent t-test on weight and height growth rate between treatment and control group.

Variable	Group	N	Mean	Std. Deviation	Mean Difference	t-test		
						t-value	df	p-value
Weight growth rate	Control	15	4.440	1.928	0.477	0.533	271	0.594
	Treatment	258	4.917	3.430				
Height growth rate	Control	15	4.547	2.448	1.868	2.833	271	0.005
	Treatment	258	6.415	2.484				

An independent t-test is further carried out to see whether there is a significant different in growth rate among treatment group based on gender. Among treatment group, 125 (48%) patients were identified as males and 133 (52%) were females. Figure 3 shows that the males just have a slightly lower weight growth rate

than the females. Meanwhile the growth rate for height is relatively higher among males than females. A formal test with the independent t-test can confirmed whether these differences between males and females in growth are significant or not.



**Figure 3: Plots of 95% confidence interval for growth rate of weight and height for males and females patients who received the treatment.**

The Levene's test suggests that the independent t-test for comparing weight growth rate between males and females should be carried under the assumption of equal variances since the p-value is greater than 0.05 ( $F = 0.756$ ,  $p = 0.278$ ). The independent t-test as shown in Table 3 reveals that the mean difference in weight growth rate is not statistically significant since the p-value is greater than 0.05 ( $t(256) = -0.123$ ,  $p = 0.902$ ). Thus we can conclude that the levothyroxine treatment increases weight gain at the same rate between males and females.

The Levene's test also suggests that the independent t-test for comparing height growth rate between males and females should be carried under the assumption of equal variances since the p-value is greater than 0.05 ( $F = 1.486$ ,  $p = 0.224$ ). The independent t-test as shown in Table 3 indicates that the mean difference in height growth rate is not statistically significant since the p-value is greater than 0.05 ( $t(256) = 0.688$ ,  $p = 0.492$ ). Thus we also conclude that the height gain for males and females increases at the same rate under the levothyroxine treatment.

**Table 3: Results for independent t-test on weight and height growth rate between males and female.**

Variable	Gender	N	Mean	Std. Deviation	Mean Difference	t-test		
						t-value	df	p-value
Weight growth rate	Males	125	4.890	3.901	-0.053	-0.123	256	0.902
	Females	133	4.943	2.936				
Height growth rate	Males	125	6.524	2.628	0.213	0.688	256	0.492
	Females	133	6.311	2.345				

## CONCLUSION

In our results provide it shows that BMI and height are positively associated with levels of serum TSH and f T(3) but not fT(4) among euthyroid Pediatrics. Longitudinal studies are needed to define the temporality of these associations and their potential health implications.

## Conflict of interest statement

The authors have declared that no competing interests exist.

## REFERENCES

- Dall'Asta C, Paganelli M, Morabito A, et al. Weight Loss Through Gastric Banding: Effects on TSH and Thyroid Hormones in Obese Subjects With Normal Thyroid Function. *Obesity*, 2010; 18(4): 854–857.
- Flegal KM, Ogden CL, Yanovski JA, et al. High adiposity and high body mass index-for-age in US children and adolescents overall and by race-ethnic group. *Am J Clin Nutr*, 2010; 91(4): 1020–6.
- Reinehr T, Isa A, de Sousa G, Dieffenbach R, Andler W. Thyroid hormones and their relation to weight status. *Hormone research*, 2008; 70(1): 51–7.
- Marzullo P, Minocci A, Tagliaferri MA, et al. Investigations of thyroid hormones and antibodies in obesity: leptin levels are associated with thyroid autoimmunity independent of bioanthropometric, hormonal, and weight-related determinants. *J Clin Endocrinol Metab*, 2010; 95(8): 3965–72.
- Manji N, Boelaert K, Sheppard MC, Holder RL, Gough SC, Franklyn JA. Lack of association between serum TSH or free T4 and body mass index

- in euthyroid subjects. *Clinical endocrinology*, 2006; 64(2): 125–8.
6. Aeberli I, Jung A, Murer SB, et al. During rapid weight loss in obese children, reductions in TSH predict improvements in insulin sensitivity independent of changes in body weight or fat. *The Journal of clinical endocrinology and metabolism*, 2010; 95(12): 5412–8.
  7. Brufani C, Manco M, Nobili V, Fintini D, Barbetti F, Cappa M. Thyroid function tests in obese prepubertal children: correlations with insulin sensitivity and body fat distribution. *Horm Res Paediatr*, 2012; 78(2): 100–5.
  8. Brienza C, Grandone A, Di Salvo G, et al. Subclinical hypothyroidism and myocardial function in obese children. *Nutr Metab Cardiovasc Dis.*, 2012.
  9. Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. *The Journal of clinical endocrinology and metabolism*, 2006; 91(8): 3088–91.
  10. Soriguer F, Valdes S, Morcillo S, et al. Thyroid hormone levels predict the change in body weight: a prospective study. *European journal of clinical investigation*, 2011; 41(11): 1202–9.
  11. Rotondi M, Leporati P, La Manna A, Pirali B, Mondello T, et al. Raised serum TSH levels in patients with morbid obesity: is it enough to diagnose subclinical hypothyroidism? *Eur J Endocrinol*, 2009; 160: 403–408.
  12. Knudsen N, Laurberg P, Rasmussen LB, Bülow I, Perrild H, et al. Small differences in thyroid function may be important for body mass index and the occurrence of obesity in the population. *J Clin Endocrinol Metab*, 2005; 90: 4019–4024.
  13. De Pergola G, Ciampolillo A, Paolotti S, Trerotoli P, Giorgino R. Free triiodothyronine and thyroid stimulating hormone are directly associated with waist circumference, independently of insulin resistance, metabolic parameters and blood pressure in overweight and obese women. *Clin Endocrinol (Oxf)*, 2007; 67: 265–269.
  14. Shon HS, Jung ED, Kim SH, Lee JH. Free T4 is negatively correlated with body mass index in euthyroid women. *Korean J Intern Med.*, 2008; 23: 53–57.
  15. Makepeace AE, Bremner AP, O'Leary P, Leedman PJ, Feddema P, et al. Significant inverse relationship between serum free T4 concentration and body mass index in euthyroid subjects: differences between smokers and nonsmokers. *Clin Endocrinol (Oxf)*, 2008; 69: 648–652.
  16. Manji N, Boelaert K, Sheppard MC, Holder RL, Gough SC, et al. Lack of association between serum TSH or free T4 and body mass index in euthyroid subjects. *Clin Endocrinol (Oxf)*, 2006; 64: 125–128.
  17. Belin RM, Astor BC, Powe NR, Ladenson PW. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the third National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab*, 2004; 89: 6077–6086.
  18. DHHS, editor. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. 2007–2008 Public Data General Release File Documentation. CDC, National Center for Health Statistics, Atlanta, GA.
  19. Caldwell KL, Makhmudov A, Ely E, Jones RL, Wang RY. Iodine status of the U.S. population, 2005–2006 and 2007–2008. *Thyroid*, 2011; 21: 419–427.
  20. Centers for Disease Control and Prevention. National Health and Nutrition Examination Survey. 2007–2008 Lab Methods. [http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/lab\\_methods\\_07\\_08.htm](http://www.cdc.gov/nchs/nhanes/nhanes2007-2008/lab_methods_07_08.htm) (accessed February 1, 2012). CDC, National Center for Health Statistics, Atlanta, GA.
  21. Reinehr T, de Sousa G, Andler W. Hyperthyrotropinemia in obese children is reversible after weight loss and is not related to lipids. *J Clin Endocrinol Metab*, 2006; 91: 3088–3091.
  22. Onur S, Haas V, Bosy-Westphal A, Hauer M, Paul T, et al. L-Tri-iodothyronine is a major determinant of resting energy expenditure in underweight patients with anorexia nervosa and during weight gain. *Eur J Endocrinol*, 2005; 152: 179–184.
  23. Kok P, Roelfsema F, Langendonk JG, de Wit CC, Frölich M, et al. High circulating thyrotropin levels in obese women are reduced after body weight loss induced by caloric restriction. *J Clin Endocrinol Metab*, 2005; 90: 4659–4663.